WASF2 Knockout U2OS Cell Line

The WASF2 Knockout U2OS Cell Line is a CRISPR/Cas9-edited knockout cell line featuring targeted disruption of the WASF2 gene, which encodes the WAVE2 protein, a central regulator of actin cytoskeleton dynamics. This stable loss-of-function model allows researchers to dissect WASF2-dependent cellular processes such as cell migration, invasion, and cytoskeletal reorganization without the confounding variables of transient knockdown strategies, making it an invaluable tool for cancer biology studies.

The U2OS cell line was established from a moderately differentiated osteosarcoma of the tibia in a female patient and is characterized by its epithelial-like morphology. Widely employed in cancer research and DNA repair studies, U2OS cells exhibit robust adherent growth and genetic tractability. As a bone cancer-derived model, they provide a physiologically relevant context for examining the molecular mechanisms that drive tumor cell dissemination and metastasis, making them an ideal host for investigating the role of WASF2 in these processes.

WASF2 (WAVE2) operates downstream of the Rac1 GTPase, a master regulator of actin polymerization. Upon Rac1 activation, WASF2 assembles into the WAVE regulatory complex (WRC) with CYFIP1, NCKAP1, ABI1/ABI2, and HSPC300, which then stimulates the Arp2/3 complex to nucleate branched actin filaments. This signaling cascade, also modulated by upstream kinases such as Abl, EGFR, and SRC, and PI3K, leads to lamellipodia formation and focal adhesion dynamics. Through its interactions with IRSp53 and Ena/VASP proteins, WASF2 coordinates actin remodeling to drive cell motility, integrating cues from VEGF and integrin signaling pathways.

In the U2OS osteosarcoma model, genetic inactivation of WASF2 severely impairs actin cytoskeleton organization and cell migration. The absence of functional WAVE2 abolishes lamellipodia formation, leading to diminished directional movement and attenuated invasive capacity. This knockout cell line thus provides a powerful platform for dissecting how WASF2-mediated actin remodeling contributes to the metastatic phenotype of bone cancer cells, and for exploring its interplay with other motility-regulating pathways, including those downstream of the insulin receptor and Abl kinase.

The WASF2 Knockout U2OS Cell Line is suited for a variety of functional assays, including wound healing, transwell migration, and Matrigel invasion assays to quantify migratory and invasive potential. Fluorescence-based phalloidin staining and immunofluorescence enable visualization of F-actin architecture, while Western blotting and co-immunoprecipitation allow analysis of WASF2-containing protein complexes and downstream effectors like the Arp2/3 complex. Additionally, Rac1 activity pull-down assays and in vitro actin polymerization assays can be performed. This cell line supports drug discovery efforts targeting metastatic spread and serves as a robust tool for siRNA/shRNA target validation. For further details, please contact Ascent Research.